Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells.
Tomoyuki KogaIsaac A ChaimJorge A BenitezSebastian MarkmillerAlison D ParisianRobert F HevnerKristen M TurnerFlorian M HessenauerMatteo D'AntonioNam-Phuong D NguyenShahram SaberiJianhui MaShunichiro MikiAntonia D BoyerJohn RavitsKelly A FrazerVineet BafnaClark C ChenPaul S MischelGene W YeoFrank B FurnariPublished in: Nature communications (2020)
Many cellular models aimed at elucidating cancer biology do not recapitulate pathobiology including tumor heterogeneity, an inherent feature of cancer that underlies treatment resistance. Here we introduce a cancer modeling paradigm using genetically engineered human pluripotent stem cells (hiPSCs) that captures authentic cancer pathobiology. Orthotopic engraftment of the neural progenitor cells derived from hiPSCs that have been genome-edited to contain tumor-associated genetic driver mutations revealed by The Cancer Genome Atlas project for glioblastoma (GBM) results in formation of high-grade gliomas. Similar to patient-derived GBM, these models harbor inter-tumor heterogeneity resembling different GBM molecular subtypes, intra-tumor heterogeneity, and extrachromosomal DNA amplification. Re-engraftment of these primary tumor neurospheres generates secondary tumors with features characteristic of patient samples and present mutation-dependent patterns of tumor evolution. These cancer avatar models provide a platform for comprehensive longitudinal assessment of human tumor development as governed by molecular subtype mutations and lineage-restricted differentiation.